Vivos posts early IsoPet traction and FDA progress but faces heavy losses, cash burn, dilution

Vivos Inc (PINK: RDGL)

Short take - what's happening inside: management is prioritizing animal therapy (IsoPet®) while progressing regulatory work for human RadioGel™ (Breakthrough Device designation granted Dec 2023). The company raised capital in H1 2025 (Reg A+), built initial inventory and production relationships, expanded activity in India, but remains loss-making and flagged as a going-concern with concentrated customers and elevated cash burn.

Key points & statistics
* Cash (June 30, 2025): $2,660,590
* Total assets: $2,775,556; Total liabilities: $96,458; Working capital / Stockholders' equity: $2,679,098
* Shares outstanding (Aug 13, 2025): 453,804,006
* Six months ended June 30, 2025 - Revenues: $41,748 (vs $18,000 in 2024)
* Six months - Cost of goods sold: $85,583; Gross loss: $(43,835)
* Six months - Operating expenses: $1,494,470; Operating loss: $(1,538,305)
* Six months - Net loss: $(1,480,209) (vs $(1,061,997) prior year)
* Three months ended June 30, 2025 - Revenue: $15,000; COGS: $49,753; Net loss: $(645,513)
* Net cash used in operating activities (six months): $(1,059,708); Net cash provided by financing: $1,507,750 (proceeds from common stock & warrants $1,506,250)
* Inventory (first recognized Feb 2025): $62,961
* RSU expense recognized (six months): $494,935; unrecognized RSU expense remaining: $655,345
* Accumulated deficit: $(86,841,438)
* Potential dilutive securities (June 30, 2025): 84,227,379
* Customer concentration: two customers represent 100% of accounts receivable; three and one customer(s) accounted for revenue >10% (note)

Positive aspects (income statement & operations)
* Revenue growth off a very small base: $41,748 for six months 2025 vs $18,000 in H1 2024 - early commercial traction in IsoPet® services, certifications and sales.
* Management is investing in R&D and certification activity (R&D up to $227,246 for six months), indicating product development momentum.
* Financing activity provided immediate runway: $1.506M raised in H1 2025 via Regulation A+ offering and warrants; cash increased by $448,042 over the period.
* Strategic progress: FDA Breakthrough Device designation (Dec 2023), business development in India, distribution agreement for hydrogel (Akina), and an effort to add a second domestic production site.

Negative aspects (income statement & risks)
* Gross loss: COGS ($85,583) exceeds revenues ($41,748) for the six-month period - the business is not yet producing margin-positive sales.
* Heavy operating expenses: $1.49M in six months, driven by professional fees, RSU vesting and G&A - operating expense dwarfs revenue.
* Widening net loss year-over-year: net loss increased to $(1,480,209) from $(1,061,997). High burn relative to cash on hand.
* Cash burn & runway risk: operating cash use $(1.06M) in six months while management says it requires approximately $3.0M annually and ~$9.0M over 36 months to execute plans.
* Going concern: auditors expressed substantial doubt about ability to continue as a going concern if additional capital is not secured.
* Customer concentration: revenues and receivables are concentrated, increasing execution and credit risk.
* Large accumulated deficit $(86.84M) and meaningful potential dilution from convertible securities, RSUs, options and warrants.

Near-term catalysts & what to watch
* FDA/IDE progress (management expects to leverage animal + human data - IDE activity noted for Q3 2025).
* Additional capital raises or licensing/partnership deals - required to fund operations and clinical studies.
* Sales ramp and margin improvement from inventory usage and certification revenue (management targets breakeven for Animal Therapy Division in 2026).
* Concentration & receivable trends - diversification of customer base is critical to reduce risk.
* RSU/warrant exercises and share dilution moves - monitor outstanding potential dilutive securities and cash inflows from exercises.

Bottom line: Vivos (PINK: RDGL) shows early commercial activity and strategic progress on regulatory and distribution fronts, but today's income statement shows COGS > revenue, large operating losses, and significant cash burn. The company's immediate viability depends on continued fundraising or strategic partnerships and execution against FDA/India plans.